Diabetes Researchers Say FDA Is Slowing Artificial Pancreas Efforts
This article was originally published in The Pink Sheet Daily
The U.S. is "desperately behind the curve," as a "result of regulatory policy that is just not working in the interest of people who live with type 1 diabetes," JDRF CEO says.
You may also be interested in...
Since 2003, FDA has approved 16 investigational device exemptions for companies to begin trials on "artificial pancreas" devices, yet the agency is questioning what constitutes an appropriate study design for the products.
The Juvenile Diabetes Research Foundation has begun partnering with device companies to speed the commercialization of artificial pancreas technology that would take some of the guesswork out of diabetes management
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.